FOSRENOL significantly reduces tablet burden for end-stage renal patients with hyperphosphatemia According to data presented today at the National Kidney Foundation's (NKF) 2006 clinical meeting in Chicago, IL, a conversion to the non-calcium phosphate binder FOSRENOL (lanthanum carbonate) from other phosphate binder therapies provides continued mean serum phosphorus control for end-stage renal disease (ESRD) patients with hyperphosphatemia,... view more... (2006-04-21)
Fosrenol data show evidence of trends towards improved bone formation in CKD stage 5 patients Treatment with the phosphate binder FOSRENOL(R) (lanthanum carbonate) was associated with slight improvements in bone formation in chronic kidney disease (CKD) Stage 5 patients with hyperphosphatemia (high phosphorus levels in the blood), according to long-term (two-year) data presented at the American Society of Nephrology (ASN) meeting. view more (2006-11-20)
